Mechanism-Based Inactivation of Cytochrome P450 2B6 by Methadone through Destruction of Prosthetic Heme

Hemali T. Amunugama, Haoming Zhang, and Paul F. Hollenberg

Department of Pharmacology, University of Michigan, Ann Arbor, Michigan

Received March 29, 2012; accepted June 8, 2012

ABSTRACT:

Methadone is a \( \mu \)-opioid receptor agonist widely used in the treatment of narcotic addiction and chronic pain conditions. Methadone is metabolized predominantly in the liver by cytochromes P450 to its pharmacologically inactive primary metabolite 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine. Initial in vitro data suggested that CYP3A4 is the major isof orm responsible for the in vivo clearance of methadone in humans. However, recent clinical data have indicated that CYP2B6 is actually the major isof orm responsible for methadone metabolism and clearance in vivo. In this study, methadone was shown to act as a mechanism-based inactivator of CYP2B6. Methadone inactivates CYP2B6 in a time-, concentration-, and NADPH-dependent manner with a \( k_I = 10.0 \, \mu M \) and \( k_{inact} = 0.027 \, \text{min}^{-1} \). The loss of CYP2B6 activity in the presence of methadone and NADPH occurred with concomitant loss of the reduced CO spectrum of the P450. Moreover, there was good correlation between the loss of CYP2B6 activity and the loss of the CO-binding spectrum. High-performance liquid chromatography-mass spectrometry analysis of the native heme of the inactivated CYP2B6 demonstrated that approximately 75% loss of heme was accompanied by comparable inactivation of CYP2B6. Liquid chromatography-mass spectrometry analysis did not reveal the formation of a protein adduct during the inactivation. The evidence strongly suggests that destruction of prosthetic heme is the underlying mechanism leading to the inactivation of CYP2B6 by methadone.

Introduction

Methadone, a synthetic opioid with a long elimination half-life, is widely used in the treatment of narcotic addiction and pain management. Methadone was first introduced to the United States in 1947. Since then, the clinical use of methadone has increased rapidly. The total number of methadone prescriptions increased by 1300% from 1997 to 2006 (Kharasch et al., 2009; Lu et al., 2010). As a consequence of this increased usage of methadone, the number of methadone-associated fatalities has gone up by 390%, and the amount of adverse events has gone up by 1800% from 1997 to 2004 (Kharasch et al., 2009). These statistics are presumably due to the use of methadone in the management of various pain conditions rather than in the treatment of addiction (Kharasch et al., 2009). Despite all of the negative attention methadone has received on the basis of these statistics, it is a very useful drug with unique pharmacological properties, including its high potency and efficacy, high oral bioavailability, no known formation of biologically active metabolites, and faster onset than morphine (Clark, 2008; Li et al., 2008).

Methadone is administered as a racemic mixture of R- and S-isomers although the R-isomer is believed to be the isomer responsible for analgesic activity. R-Methadone binds to the \( \mu \)-opioid receptor with high affinity and causes analgesia. Moreover, both R- and S-isomers bind at the N-methyl-D-aspartate receptor and inhibit the reuptake of serotonin and noradrenaline (Leppert, 2009). Methadone is predominately metabolized in the liver by several cytochromes P450 (P450) to its pharmacologically inactive primary metabolite 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine and subsequently to its secondary metabolite 2-ethyl-5-methyl-3,3-diphenyl-pyrrolidine, as illustrated in Fig. 1 (Sporkert and Pragst, 2000). P450-mediated \( \rho \)-hydroxylation of one of the aromatic rings has also been reported (Sullivan and Due, 1973; Anggård et al., 1975; Foster et al., 1999). Initial in vitro data suggested that CYP3A4 is the major isof orm responsible for the in vivo clearance of methadone in humans (Iribarne et al., 1996; Iribarne et al., 1997). However, recent clinical data have challenged the major role of CYP3A4 in methadone metabolism (Kharasch et al., 2009). Furthermore, the in vitro metabolism of methadone by CYP3A4 has been shown to be non-stereoselective, contrary to the metabolism of methadone in vivo, which is stereoselective. The metabolism of methadone by CYP2C19, CYP2D6, and CYP19 has also been reported (Gerber et al., 2004; Lu et al., 2010).

Recent clinical data suggest that CYP2B6 is actually the major isof orm responsible for methadone metabolism and clearance in vivo (Totah et al., 2008; Kharasch et al., 2009). CYP2B6 is expressed predominantly in the liver, and it is also expressed at lower levels in brain, lung, nasal mucosa, and trachea (Walsky et al., 2006). Although CYP2B6 was initially believed to play a relatively minor role in human drug metabolism, recent studies have demonstrated that the contribution of CYP2B6 to hepatic drug metabolism is several fold higher than previously estimated (Wang and Tompkins, 2008; Mo et al., 2009).
al., 2009). CYP2B6 has been shown to play an important role in the metabolism of several therapeutically relevant drugs including bupropion, efavirenz, and clopidogrel. Moreover, the discovery of numerous other substrates of this highly inducible CYP2B6 and the relatively higher occurrence of genetic polymorphisms have given CYP2B6 a prominent place in studies of human drug metabolism.

The large interindividual variability that has been observed in response to methadone treatment has been attributed to genetic polymorphisms in the genes coding for P450s involved in methadone metabolism as well as to the polymorphisms in the transporter proteins and μ-opioid receptors (Li et al., 2008; Bunt et al., 2011).

Although methadone is a versatile drug with some very beneficial properties in certain situations, it has also been shown to exhibit harmful pharmacological properties. Our current understanding of the metabolism of methadone in humans is incomplete; our inability to accurately predict pharmacokinetics in individuals leads to adverse effects, to significant drug-drug interactions, and to a number of fatalities. A better understanding of the identity of the P450s involved in methadone metabolism, their relative contributions to methadone clearance, and their stereoselectivity for methadone metabolism will greatly enhance our ability to administer this drug safely.

In this report, the mechanism-based inactivation of CYP2B6 in the reconstituted system by methadone is described. Attempts were made to determine whether the inactivation proceeded through covalent modification of protein or heme. The absence of apoprotein adducts or stable heme adducts and the loss of the CO difference spectrum imply that the destruction of prosthetic heme is the mechanism for inactivation of CYP2B6 by methadone.

Materials and Methods

**Chemicals.** Catalase, NADPH, and glutathione were purchased from Sigma-Aldrich (St. Louis, MO). 7-Ethoxy-4-(trifluoromethyl) coumarin (EFC) was purchased from Invitrogen (Carlsbad, CA). All other chemicals and solvents were of the highest purity available from commercial sources. Racemic methadone was a generous gift from Dr. James Woods (The University of Michigan, Ann Arbor, MI).

**Overexpression and Purification of CYP2B6 and Cytochrome P450 Reductase.** Plasmid pLW01 expressing human CYP2B6 with a C-terminal His4 tag and lacking 21 N-terminal residues was expressed in Escherichia coli C41 (DE3) cells and purified using a nickel-affinity column (Sigma-Aldrich) followed by a CM-Sepharose cation exchange column as described in Scott et al. (2001) and Zhang et al. (2011). The NADPH-dependent CPR was overexpressed and purified as described previously (Zhang et al., 2009).

**Kinetics for the Mechanism-Based Inactivation of P450 2B6 by Methadone.** CYP2B6 was reconstituted with CPR in a 1:2 ratio by incubating the two proteins at room temperature for 40 min (Kenaan et al., 2010). The kinetics for the inactivation of CYP2B6 by methadone were determined at 37°C in 50 mM potassium phosphate buffer, pH 7.4. The primary reaction mixtures contained CYP2B6 (1 μM) and CPR (2 μM), 130 units of catalase, and various concentrations of methadone (0–100 μM). The reactions were initiated by the addition of NADPH to a final concentration of 1 mM. At designated times, aliquots of 6 μl of the primary reaction mixture were transferred to a secondary reaction mixture (150 μl) that contained 0.1 mM 7-EFC and 0.3 mM NADPH in 50 mM potassium phosphate, pH 7.4. The secondary reactions were terminated after incubation for 10 min by the addition of 50 μl of ice-cold acetonitrile. The fluorescence intensity of the 7-hydroxy-4-trifluoromethylcoumarin product was measured at 510 nm with excitation at 410 nm using a Victor II microtiter plate reader (PerkinElmer Life and Analytical Sciences, Waltham, MA). The fluorescence intensity was used to calculate the activity of the CYP2B6 remaining. The results are expressed as a percentage of the control sample from which methadone was omitted (Kenaan et al., 2010).

**Partition Ratio for the Mechanism-Based Inactivation of P450 2B6 by Methadone.** To determine the partition ratio, the primary reaction mixtures containing CYP2B6, CPR, catalase, NADPH (1 mM), and various concentrations of methadone (0–300 μM) were incubated for 60 min at 37°C until the inactivations were complete. The activity remaining after the inactivation of CYP2B6 was then analyzed using the secondary reaction mixture as described above. The partition ratio was then determined as described previously (Kent et al., 1997).

**Analyses of the Methadone-Inactivated CYP2B6 Protein by ESI-LC-MS.** CYP2B6 was reconstituted with CPR in a 1:2 ratio as described above for the inactivation reactions. The primary reaction mixture containing 0.5 nmol of CYP2B6 and 1 nmol of CPR was inactivated with 50 mM methadone and 1.3 mM NADPH in 100 mM potassium phosphate buffer at pH 7.4. A control sample was incubated with methadone in the absence of NADPH. After the samples were incubated at 30°C for 30 min, a 50-μl aliquot of the reaction mixture was injected onto a reverse-phase C3 column (2 × 150 mm, 5 μm; Agilent Technologies, Santa Clara, CA) and eluted into a LCQ classic ion trap mass spectrometer (Thermo Fisher Scientific, Waltham, MA). CYP2B6 was separated from the other components of the reaction mixture by eluting the column with a binary solvent containing 0.1% trifluoroacetic acid (TFA) in water (solvent A) and 0.1% TFA in acetonitrile (solvent B) using the following gradient: 30% B for 5 min, increased to 90% B using a linear gradient over 20 min, and held at 90% B for 30 min. The flow rate was 0.25 ml/min. The molecular masses of the inactivated (+NADPH) and control (−NADPH) CYP2B6 were determined by deconvolution of the apoprotein charge envelopes using BioWorks software (Thermo Fisher Scientific).

**Spectral Analysis of the Inactivated CYP2B6 and Irreversibility of Inactivation.** The primary reaction mixture was incubated with 100 μM methadone in the presence of NADPH (inactivated sample) or absence of

![Fig. 1. P450-mediated pathways for the N-demethylation of methadone.](image-url)
The primary reaction mixture were 0 (\(F_1\)), 5 (\(F_2\)), from 30 to 80% B over 30 min at a flow rate of 1 ml/min, and the column CA. The solvent system used was solvent A (0.1% TFA in water) and solvent B.

Similar to that described under Materials and Methods, the enzyme activity assay was performed in a manner described above, and the enzyme activity assay was performed as described above, and the enzyme activity assay was performed in a manner similar to that described under Kinetics for the Mechanism-Based Inactivation of P450 2B6 by Methadone.

**HPLC Analysis of Heme.** The loss of the native heme and the possible formation of heme adducts were investigated by using a Shimadzu high-performance liquid chromatography system (LC-20AB). Aliquots containing 100 pmol of the inactivated (+NADPH) and control (−NADPH) CYP2B6, which had been incubated with 50 \(\mu\)M methadone and 1 mM NADPH at 37°C. At designated times, aliquots were withdrawn for CO binding and enzyme activity assays. The CO binding assay was performed as described above, and the enzyme activity assay was performed in a manner similar to that described under Kinetics for the Mechanism-Based Inactivation of P450 2B6 by Methadone.

**Partition Ratio for the Mechanism-Based Inactivation of CYP2B6.** As shown in Fig. 3, the reduced CO difference spectrum of the methadone-inactivated CYP2B6 decreased by approximately 61% after incubation of CYP2B6 with methadone in the presence of NADPH in the reconstituted system, whereas the catalytic activity of the enzyme decreased by approximately 58%. Therefore, the decrease in the reduced CO difference spectrum is comparable to the loss in the catalytic activity of the enzyme. The removal of methadone and its reaction products by overnight dialysis of the inactivated and control samples did not lead to significant recovery of catalytic activity.

**Results**

**Mechanism-Based Inactivation of CYP2B6 by Methadone.** The kinetics for the inactivation of CYP2B6 by methadone were determined by measuring the loss of 7-EFC O-deethylating activity in the reconstituted system. As shown in Fig. 2, CYP2B6 was inactivated by methadone in a time- and concentration-dependent manner. The activity for CYP2B6 remained unchanged with time in the absence of methadone, whereas the remaining activity of CYP2B6 changed significantly with time and with increasing concentrations of methadone. From the data in Fig. 2, it was calculated that methadone inactivates CYP2B6 with a \(K_i\) of 10.0 \(\mu\)M, \(k_{\text{act}}\) = 0.027 min\(^{-1}\), and \(t_{1/2}\) of 25 min. The presence of cytochrome \(b_5\) did not alter the kinetic parameters for the inactivation CYP2B6 by methadone (data not shown). Therefore, all the subsequent experiments were performed without cytochrome \(b_5\).

**Partition Ratio for the Mechanism-Based Inactivation of CYP2B6 by Methadone.** CYP2B6 was incubated with various concentrations of methadone for 60 min, allowing the inactivation to reach completion. The percentage of activity remaining was plotted as a function of the molar ratio of methadone to CYP2B6. The partition ratio was estimated from the intercept of the linear regression line obtained for the lower ratios of methadone to CYP2B6 with the straight line derived for the higher ratios of methadone to CYP2B6. The estimated partition ratio was approximately 22 for the inactivation of CYP2B6 by methadone (Fig. 3). The residual activity of inactivated CYP2B6 was approximately 20%. Complete inactivation of the enzyme could not be achieved by increasing the ratio of methadone/CYP2B6. The inability to achieve complete inactivation has previously been observed with other mechanism-based inactivators (Lin et al., 2005; Gay et al., 2011).

**ESI-LC-MS Analysis of the Inactivated Protein.** To investigate whether the mechanism-based inactivation of CYP2B6 by methadone was due to the formation of an adduct with the apoprotein, the reconstituted CYP2B6 system was incubated with methadone in the presence or absence of NADPH for 30 min, and the proteins were analyzed by ESI-LC-MS. The mass spectra obtained after 30 min of incubation are shown in Fig. 4 (traces A and B). The deconvoluted mass spectrum of CYP2B6 in the absence of NADPH has a molecular mass of approximately 54,423.0 Da, which corresponds to the molecular mass of the unmodified CYP2B6 as calculated from the amino acid sequence. The deconvoluted mass spectrum of CYP2B6 incubated with NADPH exhibits a molecular mass of approximately 54,434.0 Da. Because the error in the ESI-LC-MS experiment is ±16 Da, no significant modification in the mass of apoprotein has occurred during the inactivation of CYP2B6 by methadone. If there had been a protein adduct, the molecular mass of the protein should increase by the molecular mass of the reactive intermediate, which in this case is approximately 294 Da.

**Changes in the Reduced CO Difference Spectrum and the Absolute Spectrum of the Methadone-Inactivated CYP2B6.** As shown in Fig. 5, the reduced CO difference spectrum of the methadone-inactivated CYP2B6 decreased by approximately 61% after incubation of CYP2B6 with methadone in the presence of NADPH in the reconstituted system, whereas the catalytic activity of the enzyme decreased by approximately 58%. Therefore, the decrease in the reduced CO difference spectrum is comparable to the loss in the catalytic activity of the enzyme. The removal of methadone and its reaction products by overnight dialysis of the inactivated and control samples did not lead to significant recovery of catalytic activity.
activity or the reduced CO difference spectra (data not shown), demonstrating that the inactivation of CYP2B6 by methadone is irreversible.

Correlation between Time-Dependent Enzyme Activity Loss and Loss of CO Binding of CYP2B6 in the Presence of Methadone. As shown in Fig. 6, the percentage of activity remaining and the CO binding of the reduced CYP2B6 inactivated by incubating with methadone and NADPH decreased over time. The loss of enzyme activity is comparable to the loss of CO binding. This type of correlation between CO loss and enzyme activity loss has been observed with other mechanism-based inactivators (Foti et al., 2011).

HPLC Analysis of Heme. HPLC analysis was performed on CYP2B6 after incubation with 50 μM methadone in the absence or presence of NADPH at 37°C for 20 min as shown in Fig. 7. The elution profiles were monitored at 400 nm for intact heme. The native heme of both the control (−NADPH) and inactivated (+NADPH) P450s eluted at approximately 18 min. A significant loss (~75%) in native heme in the inactivated sample compared with the control sample was observed. Stable heme adducts or cross-linked heme eluting either before or after the native heme peak at 18 min could not be detected, indicating that this inactivation reaction may lead to heme fragmentation or to very unstable heme adducts that cannot be detected by our HPLC methods.

Discussion

Although methadone has gained increasing acceptance as a treatment for various types of pain and for narcotic addiction, effective use
of methadone is hampered by its relatively complicated and incompletely understood pharmacokinetics. Knowledge of the identity of the P450s involved in methadone metabolism, their relative contributions to methadone clearance, and their stereoselectivity for methadone metabolism could provide valuable information for predicting potential in vivo drug-drug interactions, and this knowledge should thus prove to be very beneficial in the rational use of methadone (Totah et al., 2008). Studies by Totah et al. (2008) have demonstrated that CYP2B6 plays a significant role in the stereoselective metabolism of methadone and that CYP2B6 preferentially metabolizes the S-isomer over the R-isomer.

Our results demonstrate that methadone is a mechanism-based inactivator of CYP2B6. The loss of catalytic activity of CYP2B6 is time- and concentration-dependent and requires metabolism of methadone. The values for $K_i$ and $k_{inact}$ are 10 $\mu$M and 0.027 min$^{-1}$, respectively, indicating that methadone is a relatively potent mechanism-based inhibitor of CYP2B6. Extensive dialysis of the methadone-inactivated CYP2B6 did not lead to recovery of the catalytic activity. Furthermore, the partition ratio for this inactivation is approximately 22, which suggests that on average 22 catalytic turnovers leading to product formation occur before one inactivation event.

The mechanism-based inactivation of CYP19 by racemic methadone was reported by Lu et al. (2010) in the reconstituted system. They demonstrated that racemic methadone and 2-ethyl-1,5-dimethyl-3,3-diphenylpyrrolidine, the primary metabolite of methadone, both efficiently inactivate CYP19 in a time- and concentration-dependent manner, whereas 2-ethyl-5-methyl-3,3-diphenyl-pyrrolidine, the secondary metabolite, was found to be a much weaker inactivator of CYP19. The reported $K_i$ and $k_{inact}$ values for racemic methadone are 40.0 $\mu$M and 0.06 min$^{-1}$, respectively. No stereoselectivity was observed in methadone metabolism by CYP19. The reported $K_i$ and $k_{inact}$ values for racemic methadone are 40.0 $\mu$M and 0.06 min$^{-1}$, respectively. No stereoselectivity was observed in methadone metabolism by CYP19. The reported $K_i$ and $k_{inact}$ values for racemic methadone are 40.0 $\mu$M and 0.06 min$^{-1}$, respectively. No stereoselectivity was observed in methadone metabolism by CYP19.
However, methadone-modified heme-derived substances were not detected in the TFA/butanone extracts.

It has also been reported that P450s can be inactivated by mechanisms that involve destruction of prosthetic heme without the formation of stable, isolable heme adducts. This kind of heme destruction has been reported with inactivators such as carbon tetrachloride, resveratrol, diclofenac, and mibebradil (Guzelian and Swisher, 1979; Macdonald et al., 1982; Davies et al., 1986; Chang et al., 2001; Foti et al., 2011).

Loss of the heme chromophore due to heme fragmentation has also been observed with P450 enzymes in the presence of cumene hydroperoxide (He et al., 1998). Thus, methadone appears to behave in a manner similar to these inactivators in that it does not lead to any stable heme adducts as observed by UV and mass spectroscopy.

In summary, methadone is an effective mechanism-based inhibitor of CYP2B6. The absence of covalently labeled protein or stable heme adducts or the formation of a MI complex, when taken together with the loss of the CO binding by the reduced P450, strongly suggests that destruction of the prosthetic heme is the underlying mechanism leading to the inactivation of CYP2B6 by methadone.

Acknowledgments

We thank Dr. James Woods for providing racemic methadone and Hisia Lien for Dr. providing the purified CPR.

Authorship Contributions

Participated in research design: Amunugama, Zhang, and Hollenberg.

Conducted experiments: Amunugama and Zhang.

Performed data analysis: Amunugama and Zhang.

Wrote or contributed to the writing of the manuscript: Amunugama, Zhang, and Hollenberg.

References


